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Abstract
Background: Drug-resistant tuberculosis (DR-TB) is a looming threat to tuberculosis control in India. However, no
countrywide prevalence data are available. The burden of DR-TB in HIV-co-infected patients is likewise unknown.
Undiagnosed and untreated DR-TB among HIV-infected patients is a major cause of mortality and morbidity. We aimed to
assess the prevalence of DR-TB (defined as resistance to any anti-TB drug) in patients attending public antiretroviral
treatment (ART) centers in greater metropolitan Mumbai, India.
Methods: A cross-sectional survey was conducted among adults and children ART-center attendees. Smear microscopy,
culture and drug-susceptibility-testing (DST) against all first and second-line TB-drugs using phenotypic liquid culture
(MGIT) were conducted on all presumptive tuberculosis patients. Analyses were performed to determine DR-TB prevalence
and resistance patterns separately for new and previously treated, culture-positive TB-cases.
Results: Between March 2013 and January 2014, ART-center attendees were screened during 14135 visits, of whom 1724
had presumptive TB. Of 1724 attendees, 72 (4%) were smear-positive and 202 (12%) had a positive culture for
Mycobacterium tuberculosis. Overall DR-TB was diagnosed in 68 (34%, 95% CI: 27%–40%) TB-patients. The proportions of DR-
TB were 25% (29/114) and 44% (39/88) among new and previously treated cases respectively. The patterns of DR-TB were:
21% mono-resistant, 12% poly-resistant, 38% multidrug-resistant (MDR-TB), 21% pre-extensively-drug-resistant (MDR-TB
plus resistance to either a fluoroquinolone or second-line injectable), 6% extensively drug-resistant (XDR-TB) and 2%
extremely drug-resistant TB (XDR-TB plus resistance to any group-IV/V drug). Only previous history of TB was significantly
associated with the diagnosis of DR-TB in multivariate models.
Conclusion: The burden of DR-TB among HIV-infected patients attending public ART-centers in Mumbai was alarmingly
high, likely representing ongoing transmission in the community and health facilities. These data highlight the need to
promptly diagnose drug-resistance among all HIV-infected patients by systematically offering access to first and second-line
DST to all patients with ‘presumptive TB’ rather than ‘presumptive DR-TB’ and tailor the treatment regimen based on the
resistance patterns.
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Introduction
India is a high burden country for tuberculosis (TB) and
multidrug-resistant TB (MDR-TB). The World Health Organiza-
tion has estimated that India accounted for 26% of the total
number of TB cases worldwide in 2012, with 2.2% and 15% of the
new and retreatment cases respectively being caused by multidrug-
resistant strains [1]. Further, India is home to approximately 2.4
million people living with HIV [2] and considered to have a high
burden on account of the large absolute numbers of people living
with HIV in the country.
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Figure 1. Drug-resistant tuberculosis among HIV-infected patients with presumptive tuberculosis, Mumbai, India.
doi:10.1371/journal.pone.0110461.g001
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The dual burden of HIV and TB/DR-TB in India is
significantly high with a combined rate of 5.2%, ranging from
0.4% to 28.8% in various studies, with increasing trends noted in
states having a higher burden of HIV infection [3–7]. However,
nation-wide studies do not exist and previous studies have
occurred mainly in hospitals and tertiary care centres [2,6–11].
A crude estimate from these studies suggests that 2500–3000 HIV-
infected persons develop MDR-TB annually in India.
Country-wide or state-wide drug resistance surveys (DRS) aim
to estimate the DR-TB burden at the country or state level. While
this approach is scientifically and operationally acceptable, it may
mask significant and important variance in the magnitude of the
epidemic in different localities, communities or specific popula-
tions. For India, a vast country with an enormous burden of TB
and a relatively large burden of HIV in absolute numbers, this
statement seems to hold true; from an overcrowded impoverished
slum in Mumbai to a small isolated village in the Northern Eastern
Provinces of the country, one can assume that several different
epidemics may exist. A description of such local epidemics is
necessary so as to complement the country-wide prevalence
estimate. While there is an urgent need for a nationally
representative, country-wide DRS in India, specific studies to
identify pockets of extremely high DR-TB prevalence or extensive
drug resistance patterns are equally needed in order to advocate
for and implement effective control strategies.
The overall aim of this study was to assess the burden of drug-
susceptible and drug-resistant tuberculosis among HIV-infected
patients attending antiretroviral treatment (ART) centers in the
metropolitan area of Mumbai. The specific objectives were a) to
determine the proportion of HIV-infected patients with DR-TB
among those attending public ART centers, b) to describe drug
susceptibility patterns among Mycobacterium tuberculosis isolates
from this population, and c) to identify factors associated with TB
and drug-resistant TB among HIV patients. We aimed to
contribute to the evidence base that informs policies and practices
and help to estimate the resources needed to control the epidemic
in this specific group, as well as the community.
Methods
Ethics
The study was approved by the Institutional Ethics Committee
of Grant Medical College and Sir J.J. Group of Hospitals
(Mumbai, India), the Ethics Review Board of Me´decins Sans
Frontie`res (Geneva, Switzerland) and the Ethics Advisory Group
of the International Union Against Tuberculosis and Lung Disease
(Paris, France). The study protocol was approved by the Indian
Table 1. Demographic and clinical characteristics of HIV-infected patients with presumptive TB, Mumbai, India.
Characteristics HIV-infected patients with presumptive TB (N=1724)
n (%)
Age [years, median (IQR)] 35.0 (24.3–44.0)
Sex of patients
Male 1042 (60.4)
Female 671 (38.9)
Transgender 11 (0.6)
Family income per month (in Rupees)
Less than 3500 88 (5.1)
3500–6999 910 (52.8)
7000 and above 454 (26.3)
Patient did not disclose 272 (15.6)
TB site
Pulmonary 1688 (97.9)
Extra-pulmonary 36 (2.1)
ART status
On ART 1386 (80.4)
Pre-ART 338 (19.6)
CD4 count, last visit (in cells/ml)
Less than 200 258 (15.0)
200–349 351 (20.4)
350–499 289 (16.8)
500 and above 684 (39.7)
No information 142 (8.2)
ART duration* [months, median (IQR)] 26.0 (10.7–47.5)
Previous episode of TB
Yes 933 (54.1)
No 791 (45.9)
ART: Antiretroviral treatment* Patients on ART with available information about ART initiation date, N = 1370.
doi:10.1371/journal.pone.0110461.t001
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Council of Medical Research (ICMR), New Delhi, India.
Informed consent was obtained from all study participants.
Study design
This was a cross-sectional survey among HIV-infected adult and
paediatric patients attending public and public-private ART
clinics in the greater metropolitan Mumbai area. All patients with
presumptive pulmonary or extra-pulmonary TB were assessed
with smear microscopy and conventional liquid culture. All M.
tuberculosis isolates underwent drug susceptibility testing (DST)
for first- and second-line anti-TB drugs.
Sample size
The desired sample size was determined separately for new and
previously treated culture positive TB cases. Previous tuberculosis
treatment was defined as any anti-tuberculosis treatment reported
by the patient. Assuming a prevalence of MDR-TB of 3% among
new cases and 17% among retreated cases, based on a DST survey
conducted in Gujarat [12], a sample size of 123 confirmed new
cases and 110 confirmed retreatment cases was sought in order to
estimate the prevalence of MDR-TB, with 95% confidence
intervals having a margin of error of 3% for new cases and 7%
for retreated cases respectively.
Study setting and study population
The study was carried out in five Mumbai District AIDS
Control Society (MDACS) ART Centres [1) KEM Hospital, 2)
SION Hospital, 3) SION Centre of Excellence in Paediatric HIV
Care, 4) Godrej Hospital, Vikhroli and 5) Larsen & Toubro
Hospital, Andheri] as well as in two Maharashtra State AIDS
Control Society (MSACS) ART Centres [1) Thane Civil Hospital
and 2) Navi Mumbai (Vashi) Municipal Corporation Hospital].
All HIV-infected adult and paediatric patients enrolled in the
ART centres were potentially eligible to be enrolled in the study, if
they had presumptive pulmonary or extra-pulmonary TB based
on symptom screening, regardless of the time they were enrolled in
the centres or whether they were on ART or not at the time of the
Figure 2. Distribution of Drug-resistant tuberculosis among HIV-infected (new and previously treated) with presumptive
tuberculosis patients, Mumbai, India.
doi:10.1371/journal.pone.0110461.g002
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study. Patients on TB treatment at the time of the study were
excluded.
Recruitment and sampling procedure
All HIV-infected ART center attendees were screened by an
MSF-employed nurse during the study period. Patients with
presumptive TB were investigated using a standard diagnostic
algorithm recommended by the World Health Organization [13]
that included TB culture and DST. The nurse explained in detail
the objectives of the study to the patient and/or caregiver and
obtained the signature or thumbprint of the patient if consent was
given to participate. When pulmonary TB was presumed, two
sputum specimens were collected on the same day, one hour apart,
at each study site/hospital laboratory. When extra-pulmonary TB
(EPTB) was presumed, biological specimens (fine needle aspirates,
pleural fluid, cerebrospinal fluid, etc) were obtained from extra-
pulmonary sites. All specimens were transferred to Hinduja
Hospital Microbiology Laboratory in Mumbai for culture and
first- and second-line DST.
Conventional microscopy with Ziehl-Neelsen (ZN) staining for
acid-fast bacilli and further sputum decontamination was per-
formed using the N-acetyl-L-cysteine and sodium hydroxide
method. Concentrated sediment was inoculated in one liquid
culture tube for testing using the Mycobacterial growth indicator
tube (MGIT 960) method. Positive cultures underwent microscopy
with ZN staining to confirm cord formation, and speciation with
MPT 64 antigen detection by Immunochromatography was
carried out to confirm M. tuberculosis complex. Specimens
fulfilling the above criteria underwent further testing with
phenotypic DST using the MGIT System for the following drugs:
isoniazid, rifampicin, ethambutol, ofloxacin, moxifloxacin, kana-
mycin, capreomycin, PAS, ethionamide, clofazimine and linezolid.
Non-tuberculous Mycobacteria (NTM) speciation was done by
molecular methods using Reverse Line Blot Hybridisation.
Hinduja laboratory is quality controlled and has been accredited
for first-line DST by the WHO Supranational Reference
Laboratory in Bangalore and the College of American Patholo-
gists. The laboratory was also accredited by the TB programme
for second-line DST in December 2013; prior to this date, if a
strain was suspected to have resistance to one or more second-line
anti-TB drugs, it was sent to the National Tuberculosis Institute
Laboratory in Bangalore for confirmation.
Multidrug-resistant tuberculosis (MDR-TB) was defined as
resistance to both isoniazid and rifampicin; pre-XDR-TB was
defined as MDR-TB with additional resistance to either a
fluoroquinolone or a second-line injectable agent; and extensively
drug-resistant tuberculosis (XDR-TB) was defined as MDR-TB
with additional resistance to both a fluoroquinolone and an
injectable agent. Extremely drug-resistant tuberculosis (XXDR-
TB) was defined as XDR-TB with additional resistance to any
group IV and/or group V TB drugs (PAS, ethionamide,
clofazimine, linezolid) [13].
Management of those diagnosed with DR-TB
All patients diagnosed with MDR- or XDR-TB were managed
in accordance with the national DR-TB treatment guidelines [14],
while those with pre-XDR-TB were offered individualized
treatment with 4 drugs likely to be effective.
Data collection and analysis
Demographics, clinical and laboratory data, antiretroviral
treatment (yes/no) and duration on ART, as well as data on
Table 2. Resistance profile (first and second-line) for all drug-resistant tuberculosis patients, Mumbai, India.
Resistance profile (culture-based
DST)
Total TB
Patients
(N=68), n (%)
New TB patients
(N=29), n (%)
Previously treated
TB patients
(N=39), n (%)
H-mono 11 (16.2) 7 (24.1) 4 (10.3)
R-mono - - -
Ofx-mono 1 (1.5) 1 (3.4) -
Ofx Mfx 3 (4.4) 2 (6.9) 1 (2.6)
HE 7 (10.3) 6 (20.7) 1 (2.6)
HE Eto Ofx Mfx 1 (1.5) - 1 (2.6)
HR 10 (14.7) 4 (13.8) 6 (15.4)
HRE 6 (8.8) 2 (6.9) 4 (10.3)
HR Eto 5 (7.4) - 5 (12.8)
HR E Eto 5 (7.4) 2 (6.9) 3 (7.7)
HR Ofx Mfx E 2 (2.9) 2 (6.9) -
HR Ofx Mfx Eto 1 (1.5) 1 (3.4) -
HR Ofx Mfx E Lin 1 (1.5) - 1 (2.6)
HR Ofx Mfx E Eto 8 (11.8) 1 (3.4) 7 (17.9)
HR Ofx Mfx E Eto PAS 2 (2.9) - 2 (5.1)
HR Ofx Mfx Km Eto 1 (1.5) - 1 (2.6)
HR Ofx Mfx Km E Eto 2 (2.9) 1 (3.4) 1 (2.6)
HR Ofx Mfx Km Cm E Eto 1 (1.5) - 1 (2.6)
HR Ofx Mfx Km Cm E Eto PAS 1 (1.5) - 1 (2.6)
H-isoniazid, R-rifampicin, E-ethambutol, Eto-ethionamide, Km-kanamycin, Cm-capreomycin, Ofx-ofloxacin, Mfx-Moxifloxacin, Lin- Linezolid, PAS- para-aminosalicylic acid.
doi:10.1371/journal.pone.0110461.t002
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previous TB treatment were doubly-entered into an EpiData
database (Version 3.1, EpiData Association, Odense, Denmark),
validated and analyzed.
To identify factors associated with TB and DR-TB, univariate
and multivariate analyses were performed using Poisson and
binary logistic regression models. Factors significant (p = 0.05) on
univariate analysis were entered into the multivariate logistic
regression models. Factors were coded as categorical variables and
missing values for CD4 cell counts were imputed using a multiple
imputation method. Transgender individuals (all were male to
female) were grouped with biological males in the models. All
factors were entered as a block into multivariate logistic regression
models. Data analysis, including multivariate logistic regression
models, was conducted with SPSS Version 20.0. Armonk, NY:
IBM Corp. Released 2011).
Results
Screening for presumptive TB was carried-out during 14,135
patient visits at seven ART centers in metropolitan Mumbai
between March 2013 and January 2014 (Figure 1). Individual
patients might have been screened more than once during the
study period. A total of 1741 HIV-infected patients with
presumptive tuberculosis (TB) were identified. All of them
consented to participate in the study and were investigated for
drug-resistant TB. The sputum specimens of 17 patients were
found insufficient for laboratory investigations and had to be
excluded. Thus, 1724 (99%) of the eligible patients were included
in the study.
Patient characteristics
The median age of the 1724 patients was 35 (Inter-quartile
range, IQR: 24–44) years (Table 1) and the majority (60%) were
male. A large proportion (53%) of patients had an average family
income between 3500 and 7000 Indian National Rupees
(equivalent to 60–120 USD) per month. Most of the patients
(98%) had pulmonary TB. Among the entire study cohort, 80%
were on ART during the study period and the majority (52%) had
CD4 cell counts lower than 500 cells/mL at their last visit to an
ART center. The median duration of exposure to ART prior to
enrollment in the study was 26 months (IQR: 10.7–47.5). More
than half (933/1724) of the presumptive TB patients had had at
least one episode of active TB disease in the past.
Culture-positive and drug-resistant tuberculosis
All of the 1724 patients with presumptive TB included in the
study (Figure 1) underwent smear, culture and drug susceptibility
testing (DST). Of these, 72 (4.2%; 95% Confidence Intervals (CI):
3.3–5.2) patients had smear-positive TB while 202 (11.7%; 95%
CI: 10.3–13.3) patients had culture-positive TB. Eleven TB
Table 3. Demographic and clinical factors associated with culture-positive tuberculosis in HIV-infected patients, Mumbai, India.
Explanatory Variable
Patients with
tuberculosis
(N=202), n (%)
Patients
without
tuberculosis
(N=1522), n (%)
Chi-square/t-test
(p-value)
aPRa
(95%
CI)
Age [years, median (IQR)] 38.0 (32.0–43.3) 35.0 (22.0–44.0) 8.9 (,0.01) 0.99 (0.99–
1.00)
Sex of patients
Male 138 (13.1) 915 (86.9) 5.0 (0.02) 1.01 (0.99–
1.03)
Female 64 (9.5) 607 (90.5)
Family income per month+
(in Rupees)
Less than 5000 96 (10.9) 788 (89.1) 0.2 (0.65)
5000 and above 66 (11.6) 502 (88.4)
ART status
Pre-ART 72 (21.3) 266 (78.7) 37.3 (,0.01) 1.07 (1.04–
1.10)
On ART 130 (9.4) 1256 (90.6)
CD4 count, last visit* (in
cells/ml)
Less than 200 58 (22.5) 200 (77.5) 34.7 (,0.01) 1.08 (1.05–
1.11)
200 and above 127 (9.6) 1197 (90.4)
ART duration** [months,
median (IQR)]
19.3 (5.2–35.7) 27.1 (11.3–47.9) 9.9 (,0.01)
Previous episode of TB
Yes 88 (9.4) 845 (90.6) 10.3 (,0.01) 1.01 (0.99–
1.03)
No 114 (14.4) 677 (85.6)
ART: Antiretroviral treatment, IQR: Inter-quartile range, CI; Confidence Intervals +Patients with recorded family income, N= 1452* Patients with available information on
CD4, last visit, N = 1582** Patients on ART with available information about ART initiation date, N = 1370a aPR; adjusted Prevalence Ratios (calculated by Poisson regres-
sion using multiple imputation for CD4 missing data).
doi:10.1371/journal.pone.0110461.t003
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patients were smear-positive but culture negative and 141 patients
were culture-positive but smear-negative. Those patients having a
history of TB had a higher rate of smear-positivity (4.4% versus
3.9%), but lower culture-positivity rate (9.4% versus 14.4%) as
compared to patients without TB history (Figure 2).
Among all culture-positive TB patients, 68 or 33.7% (95% CI:
27.4–40.4) had some form of drug-resistant TB. A high proportion
of MDR-TB and pre-XDR-TB, 38% (26/68) and 21% (14/68)
respectively, was observed amongst drug-resistant TB patients.
Table 2 shows the detailed resistance patterns of all patients with
DR-TB.
Of the newly diagnosed (114/791) and previously treated (88/
933) culture-positive TB patients, 25.4% (95% CI: 18.1–34.0) and
44.3% (95% CI: 34.2–54.8) patients had drug-resistant TB. The
proportion of patients with multidrug-resistant TB and more
advanced TB resistance profiles was higher (36% versus 11%) in
previously treated patients compared to newly diagnosed TB
patients.
Children and extra-pulmonary tuberculosis patients
In the study, 283 children aged less than 15 years were
investigated. The median (IQR) age of these children was 11 (8–
13) years, just over half of them were male (56%), and sixty-eight
percent were on ART. Of the 283 children investigated, 5% (15/
283) had culture-positive TB, of whom seven (46.7%, 7/15) had
drug-resistant TB; one had polydrug-resistant TB, two had MDR-
TB and four had pre-XDR-TB.
Among 1724 HIV-infected patients investigated during the
study period, 36 patients had presumptive extra-pulmonary TB
(EPTB). The median (IQR) age of these patients was 45 (40–47)
years and three-quarters of them were male (27/36, 75%). Among
the 36 investigated presumptive EPTB patients, 14% (5/36)
patients had culture-positive TB. Of these, 40% (2/5) patients had
DR-TB: one had INH mono-resistant TB while another had pre-
XDR-TB.
Factors associated with culture-confirmed TB, DR-TB and
MDR-TB
The demographic and clinical factors were assessed for
association with culture-confirmed TB, DR-TB and MDR-TB.
The univariate and bivariate analyses found age, ART status, CD4
count at last visit and previous episode of TB significantly related
to culture-positive TB (Table 3). A multivariate Poisson regression
model showed that older age, pre-ART status (i.e. not yet on
ART), CD4 count less than 200 cells/mL at the last visit and a
previous episode of TB were associated with culture-positive TB.
None of the factors other than previous history of TB were
associated with drug-resistant TB (Table 4) and multi-drug
resistant TB (Table 5) in bivariate and multivariate binary logistic
regression models.
Table 4. Demographic and clinical factors associated with drug-resistant tuberculosis in HIV-infected tuberculosis patients,
Mumbai, India.
Explanatory
Variable
Patients with
drug-resistant
tuberculosis
(N=68), n (%)
Patients without
drug-resistant
tuberculosis
(N=134), n (%)
Chi-square/t-test
(p-value)
aORa
(95% CI)
Age [years, median (IQR)] 35.5 (28.5–42.8) 38.0 (33.8–44.0) 2.15 (0.14) 0.98 (0.96–1.01)
Sex of patients
Male 46 (33.3) 92 (66.7) 0.02 (0.88) 0.95 (0.49–1.82)
Female 22 (34.4) 42 (65.6)
Family income
per month+ (in Rupees)
Less than 5000 36 (37.5) 60 (62.5) 1.8 (0.17)
5000 and above 18 (27.3) 48 (72.7)
ART status
Pre-ART 22 (30.6) 50 (69.4) 0.48 (0.49) 0.96 (0.49–1.90)
On ART 46 (35.4) 84 (64.6)
CD4 count, last
visit* (in cells/ml)
Less than 200 19 (32.8) 39 (67.2) 0.22 (0.88) 0.96 (0.48–1.93)
200 and above 43 (33.9) 84 (66.1)
ART duration**
[months, median
(IQR)]
19.3 (5.7–31.3) 19.2 (3.2–43.7)
Previous episode
of TB
Yes 39 (44.3) 49 (55.7) 7.93 (,0.01) 2.31 (1.24–4.30)
No 29 (25.4) 85 (74.6)
ART: Antiretroviral treatment, CI; Confidence Intervals +Patients with recorded family income, N= 162* Patients with available information about CD4 count, last visit
N = 185** Patients on ART with available information about ART initiation date, N = 126a aOR; adjusted Odds ratios (calculated by binary logistic regression using multi-
ple imputation for CD4 missing data).
doi:10.1371/journal.pone.0110461.t004
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Discussion
To our knowledge this is the first DR-TB survey carried out
among HIV clinic attendees in India. This study shows that,
among HIV-infected children and adults in Mumbai, the burden
of drug-resistant tuberculosis is extremely high: almost one in four
new TB cases and one in two of those previously treated for TB
have a drug-resistant strain. Of just as great concern, a large
proportion of these strains was resistant to one or more second-line
tuberculosis drugs, especially fluoroquinolones.
The overall rate of culture positivity amongst presumptive TB
cases was surprisingly low (11.7%). We hypothesize that this was
due neither to limitations in laboratory techniques nor the
presence of NTM disease, but instead to the broad inclusion
criteria that required a person attending a study site to have just
one of four possible TB symptoms as recommended by WHO
[13]; a person with ‘current cough’, for example, who was
otherwise stable was eligible for enrolment. Another possible
contributor to the low rate of TB culture positivity was the
relatively large number of poor quality specimens (e.g. consisting
of saliva) despite active instruction being given by a dedicated
study nurse at each site. In any case, this finding warrants further
investigation.
Even though the overall yield of TB was small in the pediatric
cohort as well, it remains significant that almost half of the
children with TB were infected with drug-resistant strains, most
commonly pre-XDR-TB. Since bacteriological confirmation of
DR-TB is more challenging in young children than in adults, as
they cannot expectorate sputum and are more likely to have
paucibacillary and extra-pulmonary TB, we hypothesize that the
burden of TB and DR-TB is likely to be underestimated among
children in this study, similar to what has been found in a recent
meta-analysis [15]. With less than 2% of all study participants
having specimens taken from extrapulmonary sites, it is almost
certain that EPTB is being underdiagnosed as well in this cohort.
A separate analysis found no significant association between EPTB
and DR-TB in children or adults.
Our statistical models revealed no significant associations
between most demographic and clinical factors and the risk of
DR-TB and MDR-TB. We believe that these findings are
important for their lack of associations; it seems that most TB/
HIV co-infected patients attending ART centers in Mumbai are at
risk for DR-TB. Although the relatively small sample size limits the
power of our analyses and calls for cautious interpretation, the lack
of associations suggests that all those infected with HIV and
presumed to have active TB be tested for drug-resistant strains.
Table 5. Demographic and clinical factors associated with multidrug-resistant tuberculosis in HIV-infected tuberculosis patients,
Mumbai, India.
Explanatory
Variable
Patients with
multidrug-resistant
tuberculosis (N=45),
n (%)
Patients with
drug-susceptible
tuberculosis
(N=134), n (%)
Chi-square/t-test
(p-value)
aORa
(95% CI)
Age [years,
median (IQR)]
38.0 (30.0–42.5) 38.0 (33.8–44.0) 1.85 (0.18) 0.98 (0.95–1.01)
Sex of patients
Male 30 (24.6) 92 (75.4) 0.06 (0.80) 0.83 (3.8–1.83)
Female 15 (26.3) 42 (73.7)
Family income
per month+
(in Rupees)
Less than 5000 21 (25.9) 60 (74.1) 1.03 (0.31)
5000 and above 11 (18.6) 48 (81.4)
ART status
Pre-ART 12 (19.4) 50 (80.6) 1.69 (0.19) 0.85 (0.37–1.96)
On ART 33 (28.2) 84 (71.8)
CD4 count,
last visit*
(in cells/ml)
Less than 200 13 (25.0) 39 (75.0) 0.00 (1.00) 1.02 (0.43–2.41)
200 and above 28 (25.0) 84 (75.0)
ART duration**
[months, median
(IQR)]
19.7 (5.7–34.8) 19.2 (3.2–43.7) 0.02 (0.88)
Previous episode
of TB
Yes 32 (39.5) 49 (60.5) 16.2 (,0.01) 4.16 (1.93–8.95)
No 13 (13.2) 85 (86.7)
ART: Antiretroviral treatment, CI; Confidence Intervals +Patients with recorded family income, N= 140* Patients with available information about CD4 count, last visit
N = 164** Patients on ART with available information about ART initiation date, N = 126aaOR; adjusted Odds ratios (calculated by binary logistic regression using multi-
ple imputation for CD4 missing data).
doi:10.1371/journal.pone.0110461.t005
Burden of Drug-Rresistant TB in HIV Patients in Mumbai, India
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e110461
Given the high population density in Mumbai, in which a large
proportion of the population lives in slums under extreme poverty,
the very high TB prevalence and the relatively high HIV burden
reported in greater metropolitan Mumbai, these data are unlikely
to be representative of a country as vast and diverse as India.
Nevertheless the living conditions in Mumbai and common
practices in the public and private health sectors (as for example
the prescribing of inappropriate regimens and over-the-counter
availability of fluoroquinolones and other drugs with anti-TB
properties) are similar to those of other large metropolitan centres
in the country, so these data could very well represent the DR-TB
situation in such cities as New Delhi, Kolkata and Chennai.
While it may not be possible to generalise our estimates for the
entire country or even for HIV-uninfected populations, they serve
to highlight the overall magnitude of the DR-TB epidemic in
Mumbai, which is not unknown [16,17]. A high prevalence of
MDR-TB strains (11–68%) was reported in tertiary health
facilities as early as 1991, followed by further documentation in
2006 [18–20], including information on the magnitude of the
epidemic in children [21]. A study by D’Souza et al in 2009 [18]
documented high levels of multiple drug resistance (both MDR
and poly-drug resistance) amongst previously untreated cases in
urban parts of Mumbai. In 2011 Udwadia et al reported a cases-
series of totally-drug resistant TB (a term that has not officially
been endorsed by WHO) in Mumbai, which captured the
attention of local and international media [22,23]. However to-
date such findings are often overlooked and their importance
minimized as representing only selected populations, laboratory or
tertiary care settings and small case-series. Our study confirms that
there is more than one epidemic ongoing in Mumbai and
reinforces the urgent need to accurately measure the overall
prevalence and incidence of DR-TB around the country in order
to define appropriate interventions. Studies in selected populations
such as this complement the overall estimates and can help in
directing resources and prioritizing interventions targeted at the
most vulnerable groups.
This survey is subject to the usual limitations in survey design
and data collection. There is likely to be a tendency for patients to
not report previous treatment either because they do not
remember (recall limitation) or, on purpose, to avoid going
through a long course of treatment that includes daily injectable
medication and is known among patients for debilitating side
effects [24]. Such bias could have led to an overestimate of DR-TB
among new cases and an underestimate among retreatment cases.
However, most HIV-infected patients attending ART clinics are
usually aware of tuberculosis and have been counseled and
screened for TB on several occasions, so recall limitation is rather
unlikely.
The majority of HIV-infected patients attending public and
public-private ART centers in the city are likely to access the
public national TB programme for TB diagnosis and treatment.
However many still seek care from private practitioners or may
switch between the public and private sectors. The contribution to
DR-TB levels from suboptimal treatment regimens prescribed in
the unregulated Indian private health sector has been well
documented [25–27]. Cox et al in 2007 have shown that even
under well-established DOTS programmes in areas with high
levels of drug resistance, high levels of amplification of drug
resistance are to be expected [28].
The high level of resistance to three or more first-line anti-TB
drugs and to fluoroquinolones has been previously described by
others [29]. The proportion of previously untreated cases in our
study that were resistant to more than three drugs, especially
isoniazid, rifampicin and a fluoroquinolone, was particularly
alarming and highlights two major issues in the management of
TB in the setting of HIV/ART clinics. Firstly, it points to the
scenario of nosocomial transmission of TB and DR-TB. Those
attending an ART clinic at least once a month are more likely to
be exposed to susceptible and resistant strains of M. tuberculosis
than the general population. Given that the ART centers in
Mumbai are usually extremely busy, constantly crowded and that
they often lack adequate TB infection control interventions, this
scenario is not unlikely. Instead of hypothesizing that most cases of
DR-TB are due to non-adherence among patients on treatment,
exogenous infection or re-infection should first be considered
[30,31]. Secondly, considering the high levels of resistance to
second-line TB drugs and especially fluoroquinolones in this
population, it is reasonable to assume that patients with
presumptive TB may actually have pre-XDR-TB or even XDR-
TB. This statement implies a huge investment in laboratory
capacity in an already constrained public sector in Mumbai in
order to screen all TB patients at the outset for strains that are
resistant to fluoroquinolones and anti-TB injectables Nevertheless,
we believe that it is a reasonable investment to make if the
epidemic of DR-TB is to be controlled in the city in the future.
Conversely, if DST is only offered afterward to those failing their
TB treatment regimen, a large proportion of DR-TB cases will be
missed due to the high risk of mortality among HIV-positive
patients with untreated DR-TB [32].
There is an ongoing plan to systematically offer molecular TB
diagnosis (mainly using Xpert MTB/RIF, also known as
GeneXpert) to all HIV-infected patients in Mumbai and elsewhere
in the country. While this is a giant leap forward, since GeneXpert
can rapidly detect MTB and rifampicin resistance within 2 hours,
we are concerned that ‘scale up’ of DR-TB diagnosis using this
particular diagnostic may lead to suboptimal practices, since a
diagnosis of rifampicin resistance alone and/or assumption that it
represents a diagnosis of MDR-TB, may mask a diagnosis of pre-
XDR or XDR-TB (or worse); the risks then associated with giving
a suboptimal treatment regimen are significant both in terms of
morbidity and mortality for the patient, as well as amplification of
resistance and subsequent community transmission of resistant
strains. While GeneXpert is an excellent and efficient diagnostic
tool for MTB and screening test for DR-TB, in settings like
Mumbai it is essential that it be complemented by culture and
DST involving first- and second-line anti-TB drugs. The national
programme has recently changed the policy to account for this
risk, starting with HIV-infected patients in Mumbai and Mahar-
ashtra.
Our initial study protocol included fingerprinting studies using
spoligotyping, which we had to abandon due to the high cost. Cox
et al have in the past found a strong association between the
Beijing genotype and amplification in situations of preexisting
resistance in a central Asian setting [33]. Similarly, the proportion
of the Beijing genotype was reported to be 35% in the urban
Mumbai population studied by Almeida et al [34]. We need
fingerprinting studies to establish how often nosocomial transmis-
sion occurs and to guide TB infection control interventions.
Another area of research that is urgently needed relates to
chemoprophylaxis for child contacts of DR-TB cases in Mumbai;
preventative regimens that have shown to be effective in other
settings are unlikely to prevent development of active disease in
many children in Mumbai due to the high baseline rate of
fluoroquinolone resistance [35].
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Conclusion
Our findings strongly suggest that there is an ongoing DR-TB
epidemic among people living with HIV and attending ART
centers in Mumbai, which requires urgent, innovative and feasible
models of care that allow for rapid and accurate detection and
treatment of as many DR-TB patients as possible. Ideally all
patients with presumptive TB attending any ART center in
Mumbai, or settings with similar drug resistance patterns, should
be screened with a rapid molecular diagnostic followed by DST to
first- and second-line anti-TB drugs, including for fluoroquino-
lones, so that the correct diagnosis is made as early as possible and
followed by prompt treatment initiation with an appropriate
individualized regimen. The high rate of DR-TB amongst new TB
patients also highlights the need for better TB infection control
measures in order to prevent ongoing transmission of DR-TB in
the community and health facilities, especially those attended by
vulnerable populations, such as those living with HIV.
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